LinkedInXFacebook
Subscribe
Orthopedics This Week
  • My Feed
  • |Posts
  • |Events
  • |MSK Innovations
  • |Power Rankings
  • |Masterclasses
  • |Technology Awards
  • Press Releases
  • |Advertising
  • |Job Board
  • Spine
  • ◆Joints
  • ◆Upper Extremities
  • ◆Foot & Ankle
  • ◆Sports Medicine
  • ◆Pain Mgmt
  • ◆Trauma
  • ◆Biologics
  • ◆Technology
  • ◆People
  • ◆Company News
  • ◆Legal & Regulatory
Home/Company News/Orthofix Acquires FITBONE Limb Lengthening System
Company News

Orthofix Acquires FITBONE Limb Lengthening System

April 2, 2020 1 min read Premium comments

Advertisement

Orthofix Acquires FITBONE Limb Lengthening System
FITBONE® intramedullary lengthening system for lengthening of the femur and tibia bones. / Source: Business Wire and Orthofix Medical Inc.
#orthofixSecondary#limblengthening#fitbone

Medical device company Orthofix Medical Inc. has acquired FITBONE® and associated assets for $18 million in cash and a manufacturing supply contract with developer Wittenstein SE.

FITBONE is a lengthening nail for femur and tibia bones that can be surgically implanted through a minimally invasive procedure. The distraction process is managed through an external telemetry control set. Included with the transaction is the FITSPINE system for “fusionless surgery to treat early onset scoliosis.” FITSPINE is in preliminary development.

Orthofix President and Chief Executive Officer Jon Serbousek commented, “The acquisition of the FITBONE intramedullary lengthening system further demonstrates Orthofix’s commitment to investing in differentiated products that are a strong strategic fit within our core businesses.”

Serbousek continued, “Adding this technology to our current limb reconstruction portfolio enables us to offer physicians solutions to meet the needs of their patients which may require internal or external fixation procedures. We look forward to developing other applications of this exciting platform.”

Wittenstein is a privately held Germany-based company. Wittenstein’s subsidiary Wittenstein intens GmbH developed the FITBONE and FITSPINE systems. Regarding the sale, Wittenstein reported, “Wittenstein intens GmbH will initially maintain manufacturing operations in Harthausen for a transitional period of about two years and assist the successive transfer of know-how to Orthofix.” During the transfer, Orthofix will manage product sales.

When asked about the sale, Wittenstein Chief Executive Officer Bertram Hoffmann, Ph.D., commented, “It is increasingly difficult for a classic engineering firm like Wittenstein to take adequate account of the specific characteristics of the medtech business.”

Dr. Hoffmann continued, “We, the Supervisory Board and the owning Wittenstein family are united by a common conviction that an established, specialized company in the medtech industry is much better positioned to continue developing and perfecting Wittenstein’s medical technology successfully.”

Based in Lewisville, Texas, Orthofix is a “global medical device company focused on musculoskeletal healing products and therapies.” Orthofix’s mission is to “improve patients’ lives by providing superior reconstruction and regenerative musculoskeletal solutions to physicians worldwide.”

React:

Discussion

14
DS
Dr. Sarah MitchellOrthopedic Surgeon · Mayo Clinic

This is a fascinating development. In my practice we've seen similar outcomes with the revised protocol. The key differentiator seems to be patient selection criteria. Has anyone else noticed the correlation with BMI thresholds?

8
JT
James Thornton, MDSpine Fellow · HSS

Great point. I'd push back slightly on the conclusion, the sample size in the cited study is too small to draw population-level inferences. That said, the directional signal is compelling and worth a larger RCT.

5
RP
R. PatelSports Medicine · Stanford

We implemented a similar approach last year. Early results are promising but we're still gathering 12-month follow-up data. Happy to share our protocol if anyone is interested.

Join the conversation

Orthopedic professionals are discussing this. Sign in and upgrade to read every comment and add your voice.

Subscribe

Get Full Access

Read every OTW article and join member discussions for $24.99/month.

Get Full Access

Advertisement

Advertisement

Advertisement

Orthopedics This Week

The most trusted source in orthopedic industry news since 2005. Covering spine, joints, trauma, biologics, and the business of orthopedics.

A publication of RRY Publications, LLC

LinkedInXFacebook

Categories

  • Spine
  • Joints
  • Upper Extremities
  • Foot & Ankle
  • Sports Medicine
  • Pain Mgmt
  • Trauma
  • Biologics
  • Technology
  • People
  • Company News
  • Legal & Regulatory

Resources

  • Subscribe
  • Community Posts
  • Job Board
  • Press Release Opportunities
  • Power Rankings
  • About OTW
  • Advertise
  • Contact Us

Get Full Access

Unlimited articles, community posts, and Power Rankings.

Get Full Access

Plans start at $24.99/mo · Annual saves 20%

© 2026 Orthopedics This Week · RRY Publications, LLC

Privacy PolicyTerms of ServiceCookie Policy